ARCHIVES

FDA Auditors Spend Two Weeks At Duke, Nevins Loses Position in Reorganization

This article is from The Cancer Letter archive.

Vol. 37 No. 04 | January 28, 2011

Download PDF Visit The Full Archive

Related Articles

DCT Announces Neutron Therapy RFP Available

January 19, 1979

Two Workshops To Look For New Research Areas

October 29, 1976

Taxol Released On Compassionate Use Basis To Centers; Ohio, Columbia Begin Treatments

October 18, 1991

Rabson Recommended For NCI Acting Director, Will be Top Prospect For Permanent Appointment

August 26, 1988

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005

DCT Board Says RDOG Concept Too Expensive; Discusses Grant Funding

July 24, 1992